



## Correction to: SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction

Julie Hias<sup>1,2</sup> · Laura Hellemans<sup>1,2</sup> · Karolien Walgraeve<sup>1</sup> · Jos Tournoy<sup>3,4</sup> · Lorenz Van der Linden<sup>1,2</sup>

Published online: 16 February 2022

© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

### Correction to: **Drugs & Aging**

<https://doi.org/10.1007/s40266-022-00920-7>

In the original online version of the article Section 3.3 Clinical Relevance of the EMPEROR-Preserved Trial for Older Adults with HFpEF, the third sentence of the first paragraph, which currently reads

First, in EMPEROR-Preserved, the time to a first hospital admission for heart failure was reduced, but in absolute terms not to the same extent as was the case in EMPEROR-Reduced.

Should read:

First, in EMPEROR-Preserved, the time to a first hospital admission for heart failure was prolonged, but in absolute terms not to the same extent as was the case in EMPEROR-Reduced.

The original article has been corrected.

---

The original article can be found online at <https://doi.org/10.1007/s40266-022-00920-7>.

---

✉ Lorenz Van der Linden  
lorenz.vanderlinden@uzleuven.be

<sup>1</sup> Pharmacy Department, University Hospitals Leuven, Leuven, Belgium

<sup>2</sup> Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

<sup>3</sup> Department of Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium

<sup>4</sup> Geriatrics and Gerontology, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium